Toshifumi Yokota, PhD, FCAHS

Geciteerd door

	Alles	Sinds 2020
Citaties	8246	4264
h-index	50	36
i10-index	114	103

920

460

230

690

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202529 58 79 75 75 91 135 163 244 226 286 363 415 347 752 553 651 914 854 857 788 187

Openbare toegang

Alles bekijken

100 artikelen

0 artikelen

beschikbaar

niet beschikbaar

Op basis van financieringsmachtigingen

Medeauteurs

Rika MaruyamaUniversity of AlbertaGeverifieerd e-mailadres voor ualberta.ca
Yoshitsugu Aoki, MD, PhDNational Center of Neurology and Psychiatry, DirectorGeverifieerd e-mailadres voor ncnp.go.jp
Yusuke EchigoyaNihon UniversityGeverifieerd e-mailadres voor nihon-u.ac.jp
Akinori NakamuraDirector, National Hospital Organization Matsumoto Medical CenterGeverifieerd e-mailadres voor shinshu-u.ac.jp
Eric P HoffmanProfessor, Department of Pharmaceutical Sciences, Binghamton UniversityGeverifieerd e-mailadres voor binghamton.edu
William DuddyUniversity of UlsterGeverifieerd e-mailadres voor ulster.ac.uk
Tejal AsleshPh.D. student, University of AlbertaGeverifieerd e-mailadres voor ualberta.ca
yuko miyagoe suzuki国立精神神経医療研究センター神経研究所Geverifieerd e-mailadres voor ncnp.go.jp
Kanneboyina NagarajuSchool of Pharmacy and Pharmaceutical Sciences-Binghamton University-SUNYGeverifieerd e-mailadres voor binghamton.edu
Saeed AnwarDepartment of Medical Genetics, Faculty of Medicine and Dentistry, University of AlbertaGeverifieerd e-mailadres voor ualberta.ca
Vincent MoulySorbonne UniversitéGeverifieerd e-mailadres voor upmc.fr
Nhu TrieuMicroscopist, University of New BrunswickGeverifieerd e-mailadres voor unb.ca
Bo BaoAbdominal Imaging and Intervention Fellow, Harvard Medical SchoolGeverifieerd e-mailadres voor ualberta.ca
George Bou-GhariosProfessor of Matrix BiologyGeverifieerd e-mailadres voor liverpool.ac.uk
Stephanie DuguezNorthern Ireland Center for Stratified MedicineGeverifieerd e-mailadres voor ulster.ac.uk
Ryoichi MatsudaTokyo University of Science, the University of TokyoGeverifieerd e-mailadres voor rs.tus.ac.jp
Md Nur Ahad ShahGrad student, University of AlbertaGeverifieerd e-mailadres voor ualberta.ca
Norio MotohashiNational Center of Neurology and PsychiatryGeverifieerd e-mailadres voor ncnp.go.jp
Luis GarciaGeverifieerd e-mailadres voor myyahoo.com
Hunain KhawajaUniversity of ArizonaGeverifieerd e-mailadres voor email.arizona.edu

Volgen

Toshifumi Yokota, PhD, FCAHS

Professor, Garrett Cumming Muscular Dystrophy Canada Research Chair, University of Alberta

Geverifieerd e-mailadres voor ualberta.ca - Homepage

Musculoskeletal Diseases Antisense Spinal Muscular Atrophy Personalized Genetic Medicine


Titel Sorteren op citaties Sorteren op jaar Sorteren op titel	Geciteerd door Geciteerd door	Jaar
Eteplirsen in the treatment of Duchenne muscular dystrophy KR Lim, R Maruyama, T Yokota Drug Design, Development and Therapy 11, 533-545, 2017	1387*	2017
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles QL Lu, A Rabinowitz, YC Chen, T Yokota, HF Yin, J Alter, A Jadoon, ... Proceedings of the National Academy of Sciences 102 (1), 198-203, 2005	494	2005
Efficacy of systemic morpholino exon‐skipping in Duchenne dystrophy dogs T Yokota, Q Lu, T Partridge, M Kobayashi, A Nakamura, S Takeda, ... Annals of Neurology: Official Journal of the American Neurological …, 2009	486	2009
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy M Taniguchi-Ikeda, K Kobayashi, M Kanagawa, C Yu, K Mori, T Oda, ... Nature 478 (7367), 127-131, 2011	215	2011
Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery Y Aoki, T Yokota, T Nagata, A Nakamura, J Tanihata, T Saito, ... Proceedings of the National Academy of Sciences 109 (34), 13763-13768, 2012	195	2012
Restoring dystrophin expression in duchenne muscular dystrophy muscle: progress in exon skipping and stop codon read through EP Hoffman, A Bronson, AA Levin, S Takeda, T Yokota, AR Baudy, ... The American journal of pathology 179 (1), 12-22, 2011	176	2011
Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene M Sakamoto, K Yuasa, M Yoshimura, T Yokota, T Ikemoto, M Suzuki, ... Biochemical and biophysical research communications 293 (4), 1265-1272, 2002	156	2002
In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52–deficient mdx mouse Y Aoki, A Nakamura, T Yokota, T Saito, H Okazawa, T Nagata, S Takeda Molecular Therapy 18 (11), 1995-2005, 2010	149	2010
α1-Syntrophin modulates turnover of ABCA1 Y Munehira, T Ohnishi, S Kawamoto, A Furuya, K Shitara, M Imamura, ... Journal of Biological Chemistry 279 (15), 15091-15095, 2004	134	2004
The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy QL Lu, T Yokota, S Takeda, L Garcia, F Muntoni, T Partridge Molecular Therapy 19 (1), 9-15, 2011	128	2011
Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration T Yokota, QL Lu, JE Morgan, KE Davies, R Fisher, S Takeda, TA Partridge Journal of cell science 119 (13), 2679-2687, 2006	114	2006
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy Y Echigoya, A Nakamura, T Nagata, N Urasawa, KRQ Lim, N Trieu, ... Proceedings of the National Academy of Sciences 114 (16), 4213-4218, 2017	108	2017
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches Y Shimizu-Motohashi, H Komaki, N Motohashi, S Takeda, T Yokota, ... Journal of Personalized Medicine 9 (1), 1, 2019	104	2019
α1-syntrophin–deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration Y Hosaka, T Yokota, Y Miyagoe-Suzuki, K Yuasa, M Imamura, R Matsuda, ... The Journal of cell biology 158 (6), 1097-1107, 2002	99	2002
Optimizing exon skipping therapies for DMD T Yokota, W Duddy, T Partridge Acta Myologica 26 (3), 179–184, 2007	96	2007
Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice Y Echigoya, Y Aoki, B Miskew, D Panesar, A Touznik, T Nagata, ... Molecular Therapy-Nucleic Acids 4, e225, 2015	91	2015
Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy K Dzierlega, T Yokota Gene Therapy, 2020	90	2020
Viltolarsen for the treatment of Duchenne muscular dystrophy RR Roshmi, T Yokota Drugs Today 55 (10), 627-639, 2019	90	2019
Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges Y Echigoya, KRQ Lim, A Nakamura, T Yokota Journal of Personalized Medicine 8 (4), 41, 2018	86	2018
Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs T Yokota, A Nakamura, T Nagata, T Saito, M Kobayashi, Y Aoki, ... nucleic acid therapeutics 22 (5), 306-315, 2012	85	2012

Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.

Artikelen 1–20

Citaties per jaar

Dubbele citaties

Samengevoegde citaties

Medeauteurs toevoegenMedeauteurs

Volgen

Geciteerd door

Medeauteurs